Cyclic nucleotide analogs as carcinostatic agents

G. A. LePage, Evan M. Hersh

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Three cylcic nucleotide analogs, cyclic 3′,5′-arabinosyladenine monophosphate, cyclic 3′,5′-ribofuranosyl-6-mercaptopurine monophosphate and cyclic 3′,5′-ribofuranosyl-6-methylmercaptopurine monophosphate were tested for ability to penetrate murine tumor cells and human lymphocytes. Tests based on either tumor inhibition or inhibition of DNA synthesis in human lymphocytes undergoing blastogenesis, or both, indicated that these agents penetrated intact cells. It was demonstrated in one case (cAraMP) that the cells could convert the cyclic 3′,5′ nucleoside to 5′-nucleotide and that this had to occur intracellularly.

Original languageEnglish (US)
Pages (from-to)1918-1922
Number of pages5
JournalBiochemical and Biophysical Research Communications
Issue number5
StatePublished - Mar 10 1972
Externally publishedYes

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Cyclic nucleotide analogs as carcinostatic agents'. Together they form a unique fingerprint.

Cite this